Wide Ranks

CDTX

Cidara Therapeutics, Inc.

20.20

Top Statistics
Market Cap 220 M Forward PE -2.03 Revenue Growth -94.10 %
Current Ratio 4.25 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -211.35 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 2.25 Enterprise / Revenue -1.26 Price To Sales Trailing12 Months 4.10
Profitability
Profit Margins -211.35 % Operating Margins -3675.83 %
Balance Sheet
Total Cash 164 M Total Cash Per Share 23.35 Total Debt 4 M
Total Debt To Equity 3.28 Current Ratio 4.25 Book Value Per Share -1.81
All Measures
Short Ratio 388.00 % Message Board Id finmb_266264552 Shares Short Prior Month 65137
Return On Equity -1.53 City San Diego Uuid d09eb400-8190-3726-9b22-86bfb18853b0
Previous Close 19.59 First Trade Date Epoch Utc 1 B Book Value -1.81
Beta 0.9940 Total Debt 4 M Volume 26722
Last Split Date 1 B Fifty Two Week Low 10.00 Total Cash Per Share 23.35
Total Revenue 53 M Shares Short Previous Month Date 1 B Target Median Price 25.00
Audit Risk 10 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -3675.83 % Target Mean Price 27.33 Net Income To Common -112242000
Short Percent Of Float 0.0105 Implied Shares Outstanding 7 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 108430 Average Volume10days 108430
Total Cash 164 M Next Fiscal Year End 1 B Revenue Per Share 11.88
Held Percent Insiders 0.0473 Ebitda Margins -55.89 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 10
Regular Market Previous Close 19.59 Target Low Price 24.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 12.76 Open 19.53 Free Cashflow -323875
State CA Dividend Yield 0.00 % Return On Assets -0.1566
Time Zone Short Name EST Board Risk 4 Trailing Eps -23.90
Day Low 19.25 Address1 6310 Nancy Ridge Drive Shares Outstanding 10 M
Compensation Risk 8 Price Hint 2 Target High Price 33.00
Website https://www.cidara.com 52 Week Change 0.4245 Average Volume 33050
Forward Eps -7.81 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 420.50 % Last Split Factor 1:20 Regular Market Day High 20.20
Is_sp_500 False Profit Margins -211.35 % Debt To Equity 3.28
Fifty Two Week High 24.40 Day High 20.20 Shares Short 66976
Regular Market Open 19.53 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue -1.26 Revenue Growth -94.10 % Shares Percent Shares Out 0.0095
Operating Cashflow -124780000 Currency USD Time Zone Full Name America/New_York
Market Cap 220 M Is_nasdaq_100 False Zip 92121
Quote Type EQUITY Industry Biotechnology Long Name Cidara Therapeutics, Inc.
Overall Risk 10 Regular Market Day Low 19.25 Held Percent Institutions 0.5186
Current Price 20.20 Address2 Suite 101 Enterprise To Ebitda 2.25
Financial Currency USD Current Ratio 4.25 Gross Margins -19.30 %
Industry Disp Biotechnology Number Of Analyst Opinions 3 Country United States
Float Shares 4 M Two Hundred Day Average 13.13 Governance Epoch Date 1 B
Enterprise Value -67797664 Price To Sales Trailing12 Months 4.10 Forward PE -2.03
Regular Market Volume 26722 Ebitda -30107000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases.

The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.

It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.

The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.

The company was incorporated in 2012 and is based in San Diego, California.